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Abstract
Background In the past decades knowledge on adequate
treatment of affective disorders and awareness of the
negative consequences of long-term benzodiazepine use
increased. Therefore, a decrease in benzodiazepine use is
expected, particularly in prolonged use. The aim of this
study was to assess time trends in benzodiazepine use.
Methods and material Data from the Longitudinal Aging
Study Amsterdam (LASA) were used to investigate trends
in benzodiazepine use between 1992 and 2002 in two
population-based samples aged 55–64 years. Differences
between the two samples with respect to benzodiazepine
use and to sociodemographic, physical health and mental
health characteristics were described and tested with chi-
square tests and logistic regression analyses.
Results Benzodiazepine use remained stable over
10 years, with 7.8% in LASA-1 (n = 874) and 7.9% in
LASA-2 (n = 919) (p = 0.90) with a persisting prepon-
derance in women and in people with low education, low
income, chronic physical diseases, functional limitations,
cognitive impairment, depression, anxiety complaints,
sleep problems and when using antidepressants. Long-term
use remained high with 70% in 1992 and 80% in 2002 of
total benzodiazepine use.
Conclusion In the Dutch population aged 55–64, overall
benzodiazepine use remained stable from 1992 to 2002,
with a high proportion of long-term users, despite the effort
to reduce benzodiazepine use and the renewal of the
guidelines. More effort should be made to decrease pro-
longed benzodiazepine use in this middle-aged group,
because of the increasing risks with ageing.
Keywords Benzodiazepine use  Time trends 
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Introduction
Benzodiazepines are widely used in the treatment of anx-
iety complaints, nervousness and sleep problems [4, 16, 30,
33, 34]. Although people may beneﬁt from their anxiolytic
and hypnotic effects, when used for a longer period (more
than 2 months) benzodiazepine use may lead to addiction
problems, with withdrawal symptoms, diminishing effect
and difﬁculty in discontinuing treatment [43]. Particularly
in later life, benzodiazepines have serious adverse effects,
such as an increased risk of mobility and ADL problems
[25, 26], falling [15, 29, 45, 51] and a negative effect on
cognitive functioning [5, 10, 27, 28, 46, 54]. They can
cause sedation and impairment of driving skills [39].
Mental and physical health and cognitive performance
improve after discontinuation of benzodiazepines, partic-
ularly sleeping pills [1]. Despite these known side-effects,
benzodiazepines are widely used, also by middle-aged and
older people and often for long periods of time [2, 4, 16,
22, 30, 33, 34, 37, 38]. Although dose escalation is rare in
older people [14, 52], discontinuation of benzodiazepine
use is found to be more difﬁcult with ageing, particularly
after 45 years [12, 13, 20].
In the past decades depression and anxiety disorders
have gained a lot of attention, leading to increasing
emphasis on the importance of adequate treatment of these
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selective serotonine reuptake inhibitors (SSRI’s), which are
used in the treatment of depression as well as anxiety
disorders, have become very popular and their use has
shown a huge increase in the past decades [11, 40]. Also,
the increasing knowledge of the impact of side effects and
addiction problems of benzodiazepines has lead to the
recommendation of short-term prescription and discon-
tinuing use when possible, particularly in older people,
with a preference for the short working benzodiazepines
without pharmacologically active metabolites [28].
In the Dutch guidelines on pharmacological treatment
of anxiety disorders serotonergic antidepressants are
advised for pharmacological treatment. Benzodiazepines
are recommended for short-term treatment only, in anx-
iety disorders as well as in mood disorders, with an
exception of anxiety disorders that do no respond to two
different SSRIs [3, 41]. Furthermore, in these years
several types of psychotherapy have proven to be
effective as well in anxiety and sleep disorders, e.g.
exposure with response prevention and cognitive behav-
iour therapy, and they can be applied with or without
pharmacotherapy [3, 49]. Thus, it might be expected that
benzodiazepine use, and particularly long-term use, has
decreased in the past years due to improved clinical
practice. Another development that may have led to a
decrease in benzodiazepine use is the increase of interest
in and knowledge on physical and mental health issues
in the general population in the past decades through
the mass media and the more open communication. This
has led to an increasing awareness of positive and neg-
ative consequences of drug use and an enhanced par-
ticipation of patients in the process of medical decision-
making.
In the literature, prevalence rates of benzodiazepine use
vary between 2 and 17%, due to the variety in deﬁnitions of
benzodiazepine use and observation period [60]. Conclu-
sions on whether benzodiazepine use is stable in time are
therefore not easily made. Consistent ﬁndings are that
benzodiazepine use in women stays twice as high as in
men, and that benzodiazepine use is higher in older people
with a preponderance of long-term use [60].
Objectives
Our hypothesis is that in the past decades the development
of special treatment for anxiety disorders, the introduction
of SSRI’s and the awareness of the addiction problems and
the side effects of benzodiazepines have led to a decrease
of benzodiazepine use, with a more adequate application
and shorter use of benzodiazepines. We will investigate
this in two population-based samples taking age, sex,
income, education, physical problems, cognition, depres-
sion, anxiety, sleep problems, antidepressant use and
alcohol use, into consideration. We chose this middle-aged
group (55–64 years) because of the increasing risks of
long-term benzodiazepine use when people grow older.
Methods
Sampling and procedures
Data were derived from the Longitudinal Aging Study
Amsterdam (LASA), a longitudinal, interdisciplinary study
on the predictors and consequences of changes in auton-
omy and well-being in the ageing population [18]. Baseline
sampling procedures and characteristics of the sample have
been described in detail in previous publications [6, 8, 17].
In short, the LASA sample is based on a representative
random sample of 3,107 older adults between the ages of
55 and 85. The sample was drawn from the population
registers of 11 municipalities in three regions of the
Netherlands; each region consisted of one middle- to large-
size city and two or more rural municipalities which bor-
dered on the city, with numbers of inhabitants varying from
700,000 to 7,000 persons (n = 3,805, response rate
81.7%). The initial sample was stratiﬁed for age and sex
and was weighted according to expected mortality at mid-
term within each sex and age group, so that after 5 years
equal numbers of men and women were expected to be
alive in the separate age groups and that sufﬁcient partic-
ipants should be left to be examined after a period of
10 years. Non-response in the ﬁrst LASA-cycle was related
to age, but not to sex. Data-collection in LASA started in
1992–1993 (LASA-baseline) and participants were ques-
tioned every 3 years ever since. In 2002/2003 a new pop-
ulation sample was drawn, called LASA-2, by using the
same sampling frame and procedures as for LASA-1.
LASA-2 consisted of 1,002 respondents, with ages ranging
from 55 to 64.
To address our research question, shifts in benzodiaze-
pine use in 10 years, respondents of equal ages
(55–64 years) from both samples were selected, resulting
in 966 (LASA-1) and 1,002 (LASA-2) participants. Due to
missing information on benzodiazepine use, samples of
n = 874 (LASA-1) and 919 (LASA-2) were available for
the analyses. In both samples this selection was not related
to age, sex, or the other covariates.
All interviews were conducted in the homes of the
respondents, by specially trained and intensively super-
vised interviewers. Informed consent was obtained from
each respondent, according to the prevailing legal
requirements. The study was approved by the Medical
Ethical Committee of the VU University Medical Centre.
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Use of benzodiazepines
Use of prescribed drugs was assessed in LASA-1 and
LASA-2 by recording the medication from the drug con-
tainers in the home of the respondents, and the duration of
use was registered. The anatomical-therapeutical-chemical
(ATC) coding and categorization system for drug data
coding [44] was used to classify all medication. Benzodi-
azepines were categorised as tranquillising agents (anxio-
lytics) or sleeping pills (hypnotics). Separate nominal
variables were deﬁned, indicating the use of anxiolytic
drugs or hypnotic drugs (coded as ‘yes’ or ‘no’).
Duration of use was divided into four categories: short-
term (\1 month), moderate (1 month–1 year), long-term
([1 year) and irregular (sometimes) use. When a respon-
dent used more than one benzodiazepine, the longest use
was counted.
The elimination time and the presence of pharmaco-
logically active metabolites of the benzodiazepines were
evaluated. The elimination time was considered long when
half-life was [20 h. Presence (yes) or absence (no) of
metabolites was established.
Covariates
Sex was investigated as a covariate, because of the pre-
ponderance of women in benzodiazepine use [23, 31, 42,
55, 57, 58], and in the prevalences of depression and
anxiety disorders [32, 59].
Because socio-economic status is known to be associ-
ated with health status and health behaviour, and with
benzodiazepine use [31, 55, 58], the level of education and
the level of income were included as covariates.
The level of education was classiﬁed into three levels:
low education (elementary school not completed, elemen-
tary education), medium education (lower vocational,
general intermediate, intermediate vocational, general
secondary education) and high education (higher voca-
tional, college and university education).
Income was classiﬁed into three levels: low income
(\1,000 Euros per month), intermediate income
(1,000–3,000 Euros per month) and high income (more
than 3,000 Euros per month). Income in LASA-1 was
corrected for inﬂation of 3% per year until 2002.
Impaired physical health is associated with depression
and anxiety complaints. Therefore, chronic diseases and
functional limitations were included as independent
variables.
Chronic diseases were assessed using speciﬁc questions
on chronic non-speciﬁc lung disease, cardiac disease,
peripheral atherosclerosis, stroke, diabetes mellitus,
arthritis, malignant neoplasms and a maximum of two other
chronic diseases. The total number of diseases ranged from
0 to 9. These data were cross-checked with the General
Practitioners of the participants. Accuracy of self-report
was shown to be independent of cognitive impairment,
level of depressive symptoms and anxiety symptoms [36].
Functional limitations were measured with a question-
naire on difﬁculty experienced with several activities
(walking up and down stairs, using public transportation
and cutting own toenails). This questionnaire was validated
in the Netherlands by Van Sonsbeek [50] and Kriegsman
et al. [35].
Cognitive impairment might hamper recognition and
treatment of affective disorders, but it can also be a side
effect of benzodiazepine use. Cognitive impairment was
measured with the Mini-Mental State Examination
(MMSE), a frequently used screening instrument for global
cognitive functioning. Scores range from 0 to 30 with
higher scores indicating better cognitive performance. We
used the cut-off score of 23, with scores B23 indicating
cognitive impairment [21].
Excessive alcohol consumption may be an indication for
addiction problems, but it can also be used as self-medi-
cation in the case of withdrawal symptoms in excessive
benzodiazepine use. Alcohol consumption was assessed
with a questionnaire developed for the Netherlands Health
Interview Survey [53] and classiﬁed according to the
Garretsen Index of Present Alcohol Use [24], into three
categories (excessive/severe, moderate/light and non-
drinker).
Depressive symptoms, anxiety symptoms and sleep
problems, often the reason for benzodiazepine use, were
measured with the Centre for Epidemiologic Studies
Depression Scale (CES-D), a 20-item self-report scale
developed for use in the community [7, 47, 48]. The CES-
D ranges from 0 to 60 with higher scores indicating more
depressive symptoms. The dichotomous score based on the
commonly used cut-off score of 16 was used [9] to indicate
clinically relevant depressive symptoms. Although the
CES-D was designed for the screening of depressive
symptoms, it may also be used as a screener of anxiety
symptoms [7]. We used the particular CES-D item about
feelings of nervousness and tension (item number 10:
feeling fearful) to measure anxiety. To investigate sleep
problems we used CES-D item number 11 (sleep being
restless). This item had a good correlation with a larger
questionnaire in LASA on sleep problems and could
therefore be used as an indicator of sleep problems.
Antidepressant use was measured in the same way as
benzodiazepine use, i.e. based on information on the drug
containers, provided by the respondents. A separate nom-
inal variable was deﬁned, indicating the use of antide-
pressant drugs, coded as ‘yes’ or ‘no’.
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In order to investigate time trends, i.e. changes over time in
benzodiazepine use, the data had to be made suitable for
comparing the two cycles. Therefore, prevalence data were
weighted by age and sex, in order to reach a similar dis-
tribution of age and sex in the two study samples, with
LASA-1 as the reference. To investigate the differences in
benzodiazepine use between LASA-1 and LASA-2, i.e. to
make a comparison between the two samples possible, we
pooled the data from both samples and added the factor
‘time’ by deﬁning the variable ‘sample number’
(1 = LASA-1 and 2 = LASA-2). In this pooled data ﬁle,
ﬁrst, for descriptive purposes, the differences between
LASA-1 and LASA-2 with respect to benzodiazepine use
and all covariates were tested using chi-square tests.
Likewise, the differences between LASA-1 and LASA-2
within the groups of benzodiazepine users with respect to
the covariates were tested using chi-square tests. In the
pooled sample, associations of benzodiazepine use with the
separate covariates were investigated in bivariate analyses
using chi-square tests. To investigate the association of
time and the other covariates with benzodiazepine use in a
multivariate model, logistic regression analyses were per-
formed, with benzodiazepine use as the dependent variable,
and with time and the other covariates entered stepwise
into the model. To investigate effect modiﬁcation of the
covariates on time differences in benzodiazepine use,
logistic regression analyses with interaction-terms of time
with the covariates were performed. In the chi-square tests
and the logistic regression analyses, p values lower than
0.05 were regarded as statistically signiﬁcant.
Results
An overview of the characteristics and the differences
between LASA-1 and LASA-2 is shown in Table 1. Ben-
zodiazepine use showed no major difference between the
two samples with 7.8% in LASA-1 and 7.9% in LASA-2
(p = 0.90), nor did separate rates of tranquillising agents
(3.7 and 4.8% resp., p = 0.24) and sleeping pills (4.6 and
3.9% resp, p = 0.49). In both samples the majority of the
benzodiazepines was used for a long period. In LASA-1
26% was used during a month to a year, and 69% was used
longer than 1 year. In LASA-2 these percentages were 15
and 80%. Use of short-working benzodiazepines without
pharmacologically active metabolites increased from 56%
in LASA-1 to 65% in LASA-2.
As a consequence of the weighing procedure, age and
sex were equally distributed in the two samples. In LASA-
1 47.9% were men and in LASA-2 47.2% were men,
Table 1 Socio-demographic characteristics, physical and mental
health and benzodiazepine use in LASA-1 and LASA-2
LASA-1 LASA-2 Sample
differences
p value N = 874 N = 919
N % N %
Education
Low 268 30.7 188 20.5 0.00
Intermediate 479 54.8 532 57.9
High 127 14.5 199 21.7
Income
a
Low 135 18.9 100 11.9 0.00
Medium 370 51.7 365 43.5
High 211 29.5 375 44.6
Chronic diseases
None 310 35.5 243 26.4 0.00
One or more 564 64.5 676 73.6
Functional limitations (of #3)
None 725 83.0 667 72.6 0.00
One or more 149 17.0 252 27.4
Cognitive impairment
No: MMSE[23 848 97.0 888 96.6 0.52
Yes: MMSE B23 26 3.0 31 3.4
Depression
No 781 89.4 790 86.0 0.03
Yes (CESD C16) 93 10.6 129 14.0
Anxiety: being fearful
No 785 89.8 803 87.4 0.16
Sometimes—often 89 10.2 116 12.6
Sleep problems
Never/some of the time 753 86.2 758 82.5 0.03
Occasionally often—always 121 13.8 161 17.5
Use of alcohol
Never 129 14.8 75 8.2 0.00
Light—moderate 683 78.1 744 80.9
(very) excessive 62 7.1 100 10.9
Antidepressant users
No 861 98.5 883 96.1 0.00
Yes 13 1.5 36 3.9
Benzodiazepine users
All 68 7.8 73 7.9 0.90
Anxiolytic users 32 3.7 44 4.8 0.24
Hypnotic users 40 4.6 36 3.9 0.49
Length of benzodiazepine use
b
Short term (\1 month) 3 5.5 4 5.5 0.34
Moderate (1 month–1 year) 14 25.5 11 15.1
Long term ([1 year) 38 69.1 58 79.5
Long half-life and/or active metabolites of benzodiazepines
No 38 55.9 47 64.4 0.30
Yes 30 44.1 26 35.6
a In the questionnaire about income, respondents were able to choose the option
‘wishes not to answer’; this resulted in ‘no answer’ in 158 respondents (18.1%) in
LASA-1 and in 79 respondents (8.6%) in LASA-2. This category was left out of
the analyses
b In LASA-1 duration of benzodiazepine use was not known in 13 respondents
(19.1%), leaving 55 out of 68 benzodiazepine users available for the analyses in
length of benzodiazepine use
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LASA-2 this was 59.4 years.
The second sample was higher educated and had a
higher income despite the inﬂation correction. Further-
more, respondents in LASA-2 reported more chronic
diseases and functional limitations, and showed more
depressive symptoms. They also reported more sleep
problems. The presence of cognitive impairment and
anxiety symptoms remained rather stable in the two
samples. In LASA-2 more respondents used alcohol and
there was also a rise in the amount of alcohol used.
Furthermore, there was a remarkable increase of antide-
pressant use.
Table 2 shows time differences in benzodiazepine use
in the socio-demographic and health subgroups and
associations of benzodiazepine use with these subgroups
in the pooled sample. Although an increase of benzodi-
azepine use was found in several subgroups (e.g. in
women, in respondents with low education or low
income, and in the case of depression, anxiety and sleep
problems) and a decrease in other subgroups (e.g. men,
high education, high income, and antidepressant users),
these differences were not statistically signiﬁcant, prob-
ably due to the small numbers in several subgroups.
In the pooled sample, benzodiazepine use was signiﬁ-
cantly higher in women, and in the respondents with
chronic physical disease, functional limitations, cognitive
impairment, depression, anxiety, sleep problems and when
using an antidepressant. Benzodiazepine use was lower in
respondents with higher education, higher income and with
higher alcohol use.
Table 3 shows the odds ratios for benzodiazepine use
and time and the other covariates. The bivariate logistic
regression analyses showed statistically signiﬁcant asso-
ciations of benzodiazepine use all covariates, but
not with time and age. In the multivariate regression
analyses, controlling for all covariates including time,
benzodiazepine use was found to be associated with
female sex, and with the presence of one or more
chronic diseases, depression, sleep problems and antide-
pressant use.
Investigation of the interaction between time and the
independent variables did not show any statistically sig-
niﬁcant interaction (results not shown).
Discussion
In the present study shifts in benzodiazepine use from 1992
to 2002 were investigated in a population-based sample
aged 55–64 years.
We expected a decrease of benzodiazepine use due to
enhanced knowledge of the effects of long-term
benzodiazepine use and insight into adequate treatment of
depression, anxiety and sleep problems. However, benzo-
diazepine use remained stable. Furthermore, long-term use
remained high despite recommendations in the guidelines
to keep treatment short. However, compared with the
increase of antidepressant use in this period, the stability in
benzodiazepine use may be considered a relatively positive
ﬁnding. A trend in preference was found for short-working
benzodiazepines without pharmacological active metabo-
lites, which is also a positive ﬁnding in this middle-aged
group.
In our study, several socio-demographic characteristics
and physical health and mental health factors that are
known to be associated with benzodiazepine use showed
differences in the two samples. We found a decrease in the
prevalence of low income and low education, and an
increase in the prevalence of physical health problems,
depression, sleep problems, alcohol use and antidepressant
use. However, the shifts in the presence of these charac-
teristics and risk factors did not affect their associations
with benzodiazepine use, nor did age or sex: all factors
except time and age were associated with benzodiazepine
use. This is in line with the literature [38]. Being a woman,
having one or more chronic diseases, depression, sleep
problems and the use of antidepressant remained associated
with benzodiazepine use in the multivariate analyses and
were considered to explain the association with the other
risk factors.
In 2002, women and respondents with low education
still used more benzodiazepines. Respondents with chronic
physical disease and functional limitations still used more
benzodiazepines. Although they may diminish feelings of
distress and sleep problems, they can also cause sedation,
muscle weakness and increase the risk of falling in this
physically vulnerable group. In the respondents with cog-
nitive impairment, benzodiazepines are often used suc-
cessfully to reduce concomitant anxiety and sleep
disturbances, but they may increase memory problems and
reduce attention, alertness and mental speed. In the case of
depression, anxiety and sleep problems, benzodiazepine
use remained high, although it is recommended only for
short-term use or for support in the ﬁrst weeks of treatment
with antidepressants or psychotherapy. Prolonged use of
benzodiazepines may even worsen the depressive symp-
toms [19, 56].
The combination of benzodiazepine use and the use of
alcohol is important because of the possibility of excessive
sedation and mood disturbances. In the alcohol users ben-
zodiazepine use was lower than in the full sample, but
some respondents combined alcohol with benzodiazepine,
which may lead to important health problems, e.g. a higher
risk of falling, memory problems and trafﬁc accidents,
particularly when this group gets older.
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There are some limitations to this study. Access to two
large population-based samples with data concerning a
wide variety of relevant variables makes LASA very well
suited for an investigation of trends in benzodiazepine use.
However, within speciﬁc subgroups, the numbers using
benzodiazepines were small, which limits statistical anal-
yses in subgroups. A second limitation of the present study
is the use of self-reports. This may cause report bias, due to
problems in the recall of information from the past (chronic
disease), or to unwillingness or feelings of shame (income,
Table 2 Benzodiazepine use by socio-demographic and health measures in LASA-1 and LASA-2 and in the pooled sample (LASA 1 ? 2)
Subgroups LASA-1
N = 874
LASA-2
N = 919
Time differences
for the subgroups
p value
LASA 1 ? 2 pooled sample
N = 1,793
Subgroup differences
(in pooled sample)
p value
Benzodiazepine
users
Benzodiazepine
users
Benzodiazepine users
N % in subgroup N % in subgroup N % in subgroup
Sex
Men 21 5.0 14 3.2 0.19 35 4.1 0.00
Women 47 10.3 59 12.2 0.37 106 11.3
Education
Low 25 9.3 22 11.7 0.41 47 10.3 0.02
Intermediate 34 7.1 44 8.3 0.49 78 7.7
High 9 7.1 7 3.5 0.15 16 4.9
Income
Low 16 11.9 15 15.0 0.48 31 13.2 0.00
Medium 23 6.2 27 7.4 0.53 50 6.8
High 15 7.1 22 5.9 0.55 37 6.1
Chronic diseases
None 12 3.9 8 3.3 0.72 20 3.6 0.00
One or more 56 9.9 65 9.6 0.85 121 9.8
Functional limitations
None 46 6.3 40 6.0 0.79 86 6.2 0.00
One or more 22 14.8 33 13.1 0.64 55 13.7
Cognitive impairment
No: MMSE[23 63 7.4 67 7.5 0.93 130 7.5 0.00
Yes: MMSE B23 5 19.2 6 19.4 0.99 11 19.3
Depression
No (CESD\16) 47 6.0 42 5.3 0.55 89 5.7 0.00
Yes (CESD C16) 21 22.6 31 24.0 0.80 52 23.4
Anxiety: being fearful
No 53 6.8 49 6.1 0.60 102 6.4 0.00
Sometimes—often 15 16.9 24 20.7 0.49 39 19.0
Sleep problems
Never—sometimes 47 6.2 36 4.7 0.20 83 5.5 0.00
Occasionally often—always 21 17.4 37 23.0 0.25 58 20.6
Use of alcohol
Never 15 11.6 12 16.0 0.37 27 13.2 0.00
Light—moderate 51 7.5 56 7.5 0.97 107 7.5
(very) Excessive 2 3.2 5 5.0 0.59 7 4.3
Antidepressant use
No 62 7.2 63 7.1 0.96 125 7.2 0.00
Yes 6 46.2 10 27.8 0.23 16 32.7
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study, medication use, was recorded directly from the
containers and did not rely on self-report.
Conclusion
It was concluded that benzodiazepine use in this middle-
aged population sample remained stable from 1992 to
2002, with a majority of long-term use, despite recom-
mendations in the guidelines for short-term use. Benzo-
diazepine use remained higher in women, and in
respondents with low education, low income, chronic
physical disease, functional limitations, depression, anxi-
ety complaints, sleep problems and in those using an
antidepressant. More attention should be paid to reduce
benzodiazepine use in the middle-aged, in order to
diminish its increasing negative effects on health and
functioning when getting older. In the case of long-term
use, discontinuation programmes with a tapering-off pro-
cedure may be helpful.
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